Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.

Abstract

INTRODUCTION:

Pulmonary hypertension (PH) is characterized by enhanced pulmonary vascular resistance, which causes right ventricle (RV) pressure overload and results in right sided heart failure and death. This work investigated the effectiveness of a combined therapy with PDE5 inhibitor (PDE5i) and a new adenosine A2A receptor (A2AR) agonist in mitigating monocrotaline (MCT) induced PH in rats.

METHODS:

An in vitro isobolographic analysis was performed to identify possible synergistic relaxation effect between sildenafil and LASSBio 1359 in rat pulmonary arteries (PAs). In the in vivo experiments, PH was induced in male Wistar rats by a single intraperitoneal injection of 60 mg/kg MCT. Rats were divided into the following groups: control (saline injection only), MCT + vehicle, MCT + sildenafil, MCT + LASSBio 1359 and MCT + combination of sildenafil and LASSBio 1359. Fourteen days after the MCT injection, rats were treated daily with oral administration of the regimen therapies or vehicle for 14 days. Cardiopulmonary system function and structure were evaluated by echocardiography. RV systolic pressure and PA endothelial function were measured.

RESULTS:

Isobolographic analysis showed a synergistic interaction between sildenafil and LASSBio 1359 in rat PAs. Combined therapy with sildenafil and LASSBio 1359 but not monotreatment with low dosages of either sildenafil or LASSBio 1359 ameliorated all of PH related abnormalities in cardiopulmonary function and structure in MCT challenged rats.

CONCLUSIONS:

The combination of sildenafil and LASSBio 1359 has a synergistic interaction, suggesting that combined use of these pharmacological targets may be an alternative to improve quality of life and outcomes for PH patients.

• Authors: Allan K Alencar, Fábio I Carvalho, Ananssa M Silva, Sabrina T Martinez, Jorge A Calasans-Maia, Carlos M Fraga, Eliezer J Barreiro, Gisele Zapata-Sudo, Roberto T Sudo
• Journal: PloS one (PLoS One) Vol. 13 Issue 4 Pg. e0195047 ( 2018) ISSN: 1932-6203 [Electronic] United States
• PMID: 29677206 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 3,4-dimethoxyphenyl-N-methylbenzoylhydrazide
• Adenosine A2 Receptor Agonists
• Benzamides
• Hydrazones
• Phosphodiesterase 5 Inhibitors
• Vasodilator Agents
• Monocrotaline
• Sildenafil Citrate

Topics

• Adenosine A2 Receptor Agonists (pharmacology, therapeutic use)
• Animals
• Benzamides (pharmacology, therapeutic use)
• Drug Synergism
• Hydrazones (pharmacology, therapeutic use)
• Hypertension, Pulmonary (chemically induced, drug therapy, physiopathology)
• Male
• Monocrotaline
• Phosphodiesterase 5 Inhibitors (pharmacology, therapeutic use)
• Pulmonary Artery (drug effects, physiopathology)
• Rats
• Rats, Wistar
• Sildenafil Citrate (pharmacology, therapeutic use)
• Vasodilator Agents (pharmacology, therapeutic use)